mounjaro tirzepatide news today september 2025 Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Mounjaro and Wegovy: Price Changes

PlexusDx offers compounded tirzepatide injections and oral formulations across multiple dose strengths to support personalized treatment plans

Safety Comparison# Semaglutide# Well-characterized safety profile across thousands of patients: GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related) Discontinuation due to AEs: ~7% (STEP 1) Boxed warning: Thyroid C-cell tumors (rodent data) Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare) 8+ years of post-marketing surveillance Zovaglutide# Phase 2 safety data (303 patients, 24 weeks): GI adverse events: Present but low severity Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class) Monthly dosing showed fewer GI events than biweekly dosing No long-term safety data available No post-marketing experience The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%)

Bryony Henderson Medical Director, UK MBBS, BSc, DFFP, MRCGP Dr

I., Flynn, P

Here, we aimed to investigate their effects on male reproduction and provide safety evidence for future clinical use